Relmada Posts Narrower FY25 Loss, Advances NVD-01 Toward Phase 3 In Bladder Cancer

Relmada reported Q4 and full‑year 2025 results and highlighted strong 12‑month data for bladder‑cancer candidate NDV‑01 and a $160M PIPE financing. The combination of positive clinical data and a sizable PIPE materially reduces near‑term funding risk and is likely supportive for the equity, while company‑level financial details were not included in the article.

Analysis

Relmada reported Q4 and full‑year 2025 results and highlighted strong 12‑month data for bladder‑cancer candidate NDV‑01 and a $160M PIPE financing. The combination of positive clinical data and a sizable PIPE materially reduces near‑term funding risk and is likely supportive for the equity, while company‑level financial details were not included in the article.